Navigation Links
REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted
Date:8/12/2008

CUPERTINO, Calif., Aug. 12 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) of REMOXY(R) and granted Priority Review. The FDA typically grants Priority Review to drug candidates that have the potential to demonstrate significant improvements compared to marketed products. The FDA goal for completing review of a drug with Priority Review status is six months from the date the application was submitted. The REMOXY NDA was submitted to the FDA by Pain Therapeutics on June 10, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"We are pleased that the NDA has been accepted and that REMOXY will receive Priority Review," stated James E. Brown, DVM, President and CEO of DURECT. "The abuse of pain medications is a widespread problem in this country and addressing that issue is clearly in the public interest. We're delighted that our ORADUR(TM) technology has enabled the development of REMOXY, an investigational drug that has the potential to be the first oxycodone on the market that deters common methods of abuse."

REMOXY is being developed by Pain Therapeutics (Nasdaq: PTIE) under license from DURECT, and Pain Therapeutics has, in turn, sublicensed the commercialization rights for this drug candidate to King Pharmaceuticals (NYSE:

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
2. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
3. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
4. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
5. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
6. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
7. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)...  Recently published clinical studies of Stretta for gastroesophageal ... of evidence. This data has led to significantly expanded ... for sufferers of refractory GERD. The ... therapy as a safe and effective GERD treatment has ... to nearly 50 million Americans. The new clinical studies ...
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 12, 2007: Progen Industries Limited,(ASX: PGL; NASDAQ: PGLA) is ... data has been accepted for late breaking news,presentation by ... Progen will also be presenting the results of this ... (AACR),Annual Meeting 2007. , ,In expectation of having ...
... Good Safety Profile and Excellent,Pharmacokinetic Properties -, RESEARCH ... BioPharma, Inc., a clinical stage company developing and,commercializing ... today announced top-line results from a Phase I,clinical ... treatment,of depression and anxiety. In this study, Tyrima ...
Cached Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... are only 24 hours in a day, that doesn’t seem to ... within their busy schedules for exercise and fitness. Fortunately, one does ... in shape. Here are five ways you can reach your fitness ... Your Commute , Consider riding a bike or taking the bus ... routine. If you must use your car to get to work, ...
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... reveals there may be a link between hardening of the ... with calcium deposits in the aorta were twice as likely ... in the heart were up to four times more likely ... 60 years or older, who had been diagnosed with having ...
... potential to yield treatments for several human diseases and ... announced they have created 17 new human embryonic stem ... researchers , which is offering the cells, will use ... Their team has been investigating the insulin-producing pancreatic beta ...
... ( an evolution specialist ), helped China's SARS Epidemiology ... fingerprinted virus samples from several dozen infected people and ... provides more evidence that SARS jumps from animals to ... of new cases is crucial, before viral strains have ...
... Ever since organ transplants began, steroids have played a ... their new organ. However, the treatment is not without ... to infections, high blood pressure, elevated blood cholesterol, and ... Belgium suggests children undergoing liver transplants may fare better ...
... has increased rapidly in the last half century, and ... about 50,000 Americans will be diagnosed with it this ... for women between the ages of 30 and 50,// ... yet that artificial sun tanning can be dangerous to ...
... studies have identified genetic activity that appears to be ... a person's perceptions of reality, emotions and thought processes. ... the world's population, typically surface during the late teens ... University in New York and colleagues identified two genes/// ...
Cached Medicine News:Health News:Scientists Have Traced How The SARS Virus evolved 2Health News:Solarium use is associated with an increased risk of skin cancer 2Health News:Gene Activity connected to Schizophrenia 2
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
30 degree angled tip with 45 mm tip opening. Made with lock. Manufactured in titanium....
Angled 45 degree shafts. 7 mm from tip to bend with grooved 2 mm platform for grasping lens haptic. Serrated McPherson style handle with dull finish....
Folding forceps used for L161U. Manufactured in titanium....
Medicine Products: